Pyoderma gangrenosum-like lesion secondary to methylenetetrahydrofolate reductase mutation: an unusual presentation of a rare disease.
Pyoderma gangrenosum (PG)-like ulcerations are a rare clinical manifestation of methylenetetrahydrofolate reductase (MTHFR) mutation. We describe a patient considered to have PG who was treated with long-term high doses of systemic corticosteroids and multiple immunosuppressive agents for several ye...
| Publicado en: | BMJ Case Reports Vol. 12; no. 4; pp. 1 - 5 |
|---|---|
| Autores principales: | , , |
| Formato: | Journal Article |
| Publicado: |
BMJ Publishing Group
4/23/2019
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=136590358&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 136590358 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 1757790X B755 jtl: BMJ Case Reports issn: 1757790X maglogo: N pubinfo: dt: 4/23/2019 vid: 12 iid: 4 pid: 8280 pub: BMJ Publishing Group artinfo: ui: 136590358 10.1136/bcr-2018-228403 136590358 ppf: 1 ppct: 4 formats: tig: atl: Pyoderma gangrenosum-like lesion secondary to methylenetetrahydrofolate reductase mutation: an unusual presentation of a rare disease. aug: au: Turkowski, Yana Razvi, Syed Ahmed, Abdul Razzaque affil: Center for Blistering Diseases, Boston, Massachusetts, USA. sug: ab: Pyoderma gangrenosum (PG)-like ulcerations are a rare clinical manifestation of methylenetetrahydrofolate reductase (MTHFR) mutation. We describe a patient considered to have PG who was treated with long-term high doses of systemic corticosteroids and multiple immunosuppressive agents for several years. In spite of this continuous aggressive therapy, the lesions did not improve but continued to get worse. She developed many significant and catastrophic side effects to them. When referred to our dermatology centre, on investigation, it was discovered that she has an MTHFR mutation. It seemed reasonable to presume that PG-like lesions were related to it. Treatment with a biologically active form of folate—[6S]-5-MTHF—with vitamins B6 and B12 was initiated. It was considered to be beneficial and capable of reducing hyperhomocysteinaemia and endothelial damage consequent from it. Since the institution of this treatment, the patient has begun to show very gradual but slow and incremental improvement. pubtype: Academic Journal doctype: Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|